Cevec licenses CAP-T cell expression tech to Pevion
Cevec has exclusively licensed its transient CAP-T cell expression technology to Pevion for the manufacture and commercialisation of a protein antigen to vaccinate against an infectious disease.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs